Literature DB >> 17463169

Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.

Elena E Solomou1, Katayoun Rezvani, Stephan Mielke, Daniela Malide, Keyvan Keyvanfar, Valeria Visconte, Sachiko Kajigaya, A John Barrett, Neal S Young.   

Abstract

Regulatory T cells are believed to control the development and progression of autoimmunity by suppressing autoreactive T cells. Decreased numbers of CD4(+)CD25(+) FOXP3(+) T cells (Tregs) are associated with impaired immune homeostasis and development of autoimmune diseases. The transcription factors FOXP3 and NFAT1 have key roles in regulatory T-cell development and function. We show that Tregs are decreased at presentation in almost all patients with aplastic anemia; FOXP3 protein and mRNA levels also are significantly lower in patients with aplastic anemia and NFAT1 protein levels are decreased or absent. Transfection of FOXP3-deficient CD4(+)CD25(+) T cells from patients with a plasmid encoding wild-type NFAT1 resulted in increased FOXP3 expression in these cells. By NFAT1 knockdown in CD4(+)CD25(+) T cells, FOXP3 expression was decreased when NFAT1 expression was decreased. Our findings indicate that decreased NFAT1 could explain low FOXP3 expression and diminished Treg frequency in aplastic anemia. Treg defects are now implicated in autoimmune marrow failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17463169      PMCID: PMC1975843          DOI: 10.1182/blood-2007-01-066258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

Review 2.  The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells.

Authors:  Ethan M Shevach; Richard A DiPaolo; John Andersson; Dong-Mei Zhao; Geoffrey L Stephens; Angela M Thornton
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

Review 3.  Regulatory T cells.

Authors:  Stefan Beissert; Agatha Schwarz; Thomas Schwarz
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

4.  T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia.

Authors:  Elena E Solomou; Keyvan Keyvanfar; Neal S Young
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

5.  Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.

Authors:  Maria Serena Longhi; Munther J Hussain; Ragai R Mitry; Sunil K Arora; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

6.  Global natural regulatory T cell depletion in active systemic lupus erythematosus.

Authors:  Makoto Miyara; Zahir Amoura; Christophe Parizot; Cécile Badoual; Karim Dorgham; Salim Trad; Dominique Nochy; Patrice Debré; Jean-Charles Piette; Guy Gorochov
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

7.  Toll-like receptor 2 controls expansion and function of regulatory T cells.

Authors:  Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

Review 8.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

9.  Molecular mechanisms underlying FOXP3 induction in human T cells.

Authors:  Pierre-Yves Mantel; Nadia Ouaked; Beate Rückert; Christian Karagiannidis; Roland Welz; Kurt Blaser; Carsten B Schmidt-Weber
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  69 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 2.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

3.  TRAIL in CD8+ T cells from patients with severe aplastic anemia.

Authors:  Chunyan Liu; Mengying Zheng; Tian Zhang; Rong Fu; Huaquan Wang; Ting Wang; Weiwei Qi; Zonghong Shao
Journal:  Int J Hematol       Date:  2017-06-19       Impact factor: 2.490

4.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

5.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

6.  Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Authors:  Unsong Oh; Gregg Blevins; Caitlin Griffith; Nancy Richert; Dragan Maric; C Richard Lee; Henry McFarland; Steven Jacobson
Journal:  Arch Neurol       Date:  2009-04

7.  Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction.

Authors:  Shok Ping Lim; Benedetta Costantini; Syed A Mian; Pilar Perez Abellan; Shreyans Gandhi; Marc Martinez Llordella; Juan Jose Lozano; Rita Antunes Dos Reis; Giovanni A M Povoleri; Thanos P Mourikis; Ander Abarrategi; Linda Ariza-McNaughton; Susanne Heck; Jonathan M Irish; Giovanna Lombardi; Judith C W Marsh; Dominique Bonnet; Shahram Kordasti; Ghulam J Mufti
Journal:  Blood       Date:  2020-08-13       Impact factor: 22.113

8.  Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.

Authors:  Dae Chul Jeong; Nack Gyun Chung; Bin Cho; Yao Zou; Min Ruan; Yoshiyuki Takahashi; Hideki Muramatsu; Akira Ohara; Yoshiyuki Kosaka; Wenyu Yang; Hack Ki Kim; Xiaofan Zhu; Seiji Kojima
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

9.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 10.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.